ABCAM Plc Directorate Change (8275K)
30 June 2014 - 4:01PM
UK Regulatory
TIDMABC
RNS Number : 8275K
ABCAM Plc
30 June 2014
For immediate release 30 June 2014
ABCAM PLC
("Abcam" or "the Company")
Directorate Change
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the
supply of innovative protein research tools, announces that, after
five years as Abcam's Chairman, Mike Redmond has decided to step
down from the Board following the Annual General Meeting, which
will be held later this year. He will be succeeded as Chairman by
Murray Hennessy, who has served as a Non-Executive Director at
Abcam for the past three years.
Jonathan Milner, Abcam's Chief Executive Officer, said:"Mike's
insight and leadership have been instrumental in Abcam's successful
growth over the past five years. On behalf of the Board I would
like to extend our sincerest thanks and gratitude to him. After
three years on the Board, Murray knows Abcam very well and his
experience in international customer-facing industries and online
businesses in particular make him the ideal candidate to take over
from Mike later in the year and help lead Abcam's next phase of
growth."
Abcam + 44 (0) 1223 696 000
Jonathan Milner, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
Numis Securities - Nominated Adviser
& Joint Broker + 44 (0) 20 7260 1000
Michael Meade - Nominated Adviser
James Black - Corporate Broking
Peel Hunt LLP - Joint Broker + 44 (0) 20 7418 8900
Clare Terlouw / Jock Maxwell MacDonald
Buchanan + 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie
Cowles
Notes for editors:
About Abcam plc
Abcam plc is a leading provider of protein research tools and
services, with a wide range of products and expert technical
support, enabling scientists to analyse living cells at the
molecular level to improve the understanding of health and
disease.
Abcam is committed to providing scientists with access to the
correct reagents and tools for their research. The Company's
catalogue currently comprises more than 130,000 products and is
continually evolving to meet customer needs. The range offered
includes primary and secondary antibodies, proteins, peptides,
lysates, biochemicals, immunoassays and other kits. Abcam products
are supported by detailed, up-to-date and unbiased data on our
website.
Headquartered in Cambridge, UK, Abcam has nine global subsidiary
offices and ships to over 100 countries. The Company was founded in
1998, and now employs over 700 people. Abcam is quoted on the AIM
market of the London Stock Exchange (AIM: ABC).
To find out more, please visit www.abcam.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAKMGZVVNGGDZM
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024